Neuland Laboratories (NEULANDLAB) Fundamentals 2026 — P/E 65.1x, Revenue Analysis | SniperIQ
Neuland Laboratories (NEULANDLAB) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹23,736 Crore, trading at ₹18497.90 on the BSE. This SniperIQ fundamentals page covers Neuland Laboratories's valuation (P/E 65.1x, P/B 12.6x), profitability (net margin 18.0%), revenue (₹2,023 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Neuland Laboratories's market cap?
Neuland Laboratories (NEULANDLAB) has a market capitalization of approximately ₹23,736 Crore, trading at ₹18497.90 on the BSE. Market cap moves with the live share price.
What is Neuland Laboratories's P/E ratio?
Neuland Laboratories's trailing twelve-month P/E ratio is 65.1x, with a price-to-book (P/B) of 12.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Neuland Laboratories?
Neuland Laboratories runs a net profit margin of 18.0%, a gross margin of 47.1%, and an operating margin of 23.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Neuland Laboratories generate?
Neuland Laboratories reported revenue of ₹2,023 Crore for fiscal year 2026, with net income of ₹364 Crore and earnings per share (EPS) of 283.71. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Neuland Laboratories pay a dividend?
Neuland Laboratories offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Neuland Laboratories financially healthy?
Neuland Laboratories carries a debt-to-equity ratio of 0.16x and a current ratio of 2.09x, with a market beta of -0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Neuland Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Neuland Laboratories (NEULANDLAB) the key facts are: market cap ₹23,736 Crore, P/E 65.1x, revenue ₹2,023 Crore, 52-week range 11500-20072. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Neuland Laboratories's full fundamentals live
Get Neuland Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.